Abstract
Introduction: Chronic Hepatitis B remains most important risk factor for developing cirrhosis, hepatic decompensation and hepatocellular carcinoma. So treatment with tenofovir of HbeAg positive Chronic Hepatitis B and seroconversion is the major concern.
Aim: To see the HbeAg and HbsAg loss after receiving tenofovic therapy for 6 and 12 months.
Methodology: A hospital based prospective study conducted on 50 chronic hepatitis B infection with HbeAg antigen positive patients between age group 12 to 60 years, receiving tenofovir (300mg) was taken for study. HbeAg, HbsAg and liver enzyme status was checked at the end of 6 months and 12 months.
Results: ALT level became normal (<19mg/ml) in 37.5 % of female patients at the end of 12 months study and in male it was 67.65%. Overall biochemical response was 58%. All patients were HbeAg reactive at the end of 6 months of tenofovir therapy but 48 percent became non reactive at the end of 12 months. Overall seroconverson was 36 percent at the end of 12 months.
Conclusion: There is statistical significant number of HbeAg loss, normalization of ALT level and HbeAg seroconversion at the end of 1 year. HBV DNA level became undetectable level in all sero converted groups.
Keywords: Chronic hepatitis B; Tenofovir: Seroconverson.
References
- Lozano R,Naghavi M, Foreman K, et al.2012.Global and regional mortality from 235 causes of death for20 age groups in 1990 and 2010: A systematic analysis for the global burden of Disease Study 2010.Lancet 380:2095-2128.
- Arora U, Mann A. Prevalence of Hepatitis B virus, Hepatitis C virus and HIV in patients of chronic liver disease in Amritsar. JIACM 2007;8(1):29-31.
- Henry L.Y. Chan ,Chi Kuen Chan, Aric Josun Hui, Sing Chan, Fred Poordad et Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients With Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNA, Gastroenterology. 2014 May;146(5):1240-8.
- Yang DH, Xie YJ, Zhao NF, et al. Tenofovir disoproxil fumerate is superior to lamivudine plus adefovir in lamivudine –resistant chronic hepatitis B patients. World J Gastroenterol.2015 Mar 7;21(9):2746.
- Ke W, Liu L, Zhang C, et al. Comparison of efficacy and safety of tenofovir and entacavir in chronic hepatitis b virus infection: a systematic review and meta-analysis. PLoS One.2014 Jun 6;9(6): e98865.
- Batirel A, Guclu E, Arslan F, et al. comparable efficacy of tenofovir versus entacavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study. Int J Infect Dis. 2014 Nov; 28:153-9.
- Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumerate versus adefovir dipivoxil for chronic hepatitis B.NEJM.2008 Dec 4;359(23):2442-55.
- Hong Shi,Mingxing Huang, Guoli Lin,et al.Efficacy comparison of tenofovir and entacavir in HBeAg positive chronic hepatitis B patients with high HBV DNA. Biomed Res Int. 2016;2016:6725073.
- Batirel A, Guclu E, Arslan F et al. comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B : a multicenter real-life study. Int J Infect Dis.2014 Nov;28:153-9.
- Yang DH, Xie YJ, Zhao NF et al. tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients. World J Gastroenterol. 2015 Mar 7;21(9):2746-53.
Corresponding Author
Dr Soumya Sarathi Mondal
Sunrise Towers, T 1, Flat No 5F, 134B Beliaghata Road, Kolkata 700015, India
Phone Number: 9433563310, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
DOI: https://dx.doi.org/10.18535/jmscr/v6i9.69
